Ensartinib

Generic Name: Ensartinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₂₇Cl_₂FN_₆O_₃

CAS Number: 1370651-20-9

Unique Ingredient Identifier: SMA5ZS5B22

Background: Ensartinib is under investigation in clinical trial NCT03420508 (Treating Patients With Melanoma and ALK Alterations With Ensartinib).

Indication: 用于此前接受过克唑替尼治疗后进展的或者对克唑替尼不耐受的间变性淋巴瘤激酶（ALK）阳性的局部晚期或转移性非小细胞肺癌（NSCLC）患者的二线治疗。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

New evidence of the impact of the national drug price negotiation policy

The 2021 National Drug Price Negotiation (NDPN) policy in China significantly improved availability and utilization of anticancer drugs, with a notable decrease in cost, though regional disparities persist. The study highlights the policy's success in enhancing drug accessibility and affordability, yet calls for continuous monitoring to further improve drug availability.

pmc.ncbi.nlm.nih.gov

3 years ago

First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for Asian ALK-Rearranged NSCLC Patients

Newer generation ALK inhibitors (ALKIs) like alectinib, brigatinib, ensartinib, and lorlatinib show superior efficacy over crizotinib for Asian ALK-rearranged NSCLC patients. Ensartinib ranks highest for progression-free survival, while alectinib shows the best overall response rate. Low-dose alectinib (300 mg twice daily) is similarly effective to higher doses in Asian populations.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy